Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD77m

    Last close

    USD1.03

    ▲ 0.63 (157.50%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Ultimovacs (OSE: ULTI)

Last close As at 18/04/2024

NOK8.36

▲ −0.39 (−4.46%)

Market capitalisation

NOK288m

Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.

Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.

Latest Insights

View More

Healthcare | Flash note

Ultimovacs — Steadfast commitment to UV1 progression

Healthcare | Flash note

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Healthcare | Flash note

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

Healthcare | edison tv

Ultimovacs – executive interview
Ultimovacs_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Carlos de Sousa

    CEO

  • Gustav Gaudernack

    CSO

  • Hans Vassgård Eid

    CFO

  • Jens Bjørheim

    CMO

  • Ton Berkien

    CBO

Balance Sheet

Forecast net debt (NOKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 19.1 (94.0) (93.5)
Relative 14.6 (94.3) (93.8)
52 week high/low NOK160.4/NOK6.3

Financials

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures, including activity level adjustments, reprioritisation of operations and a 40% workforce reduction, to support runway extension to Q425 (the company estimates its cash burn will be NOK15m/quarter).

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (fd) (öre) P/E (x) P/CF (x)
2022A 0.0 (181.0) (167.8) (489.9) N/A N/A
2023A 0.0 (213.0) (189.2) (550.1) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research

Flash note

Healthcare

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Flash note

Healthcare

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

Healthcare

Flash note

Ultimovacs — Steadfast commitment to UV1 progression

edison tv

Healthcare

Ultimovacs – executive interview

Flash note

Healthcare

Ultimovacs — Another ODD boosts the off-the-shelf, universal UV1

Update

Healthcare

Ultimovacs — Universal approach with critical readouts in March
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — FDA Fast Track boosts confidence in UV1
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — INITIUM: March 2024 top-line timeline confirmed
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — TENDU results support TET platform expansion

edison tv

Healthcare

Ultimovacs – executive interview
Ultimovacs_resized

Update

Healthcare

Ultimovacs — Staying alive with UV1 in NIPU and INTIUM
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free